Vivek K. Narayan, MD, MS

Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM, Hwang WT, Lal P, Carpenter EL, Maude SL, Plesa G, Vapiwala N, Chew A, Moniak M, Sebro RA, Farwell MD, Marshall A, Gilmore J, Lledo L, Dengel K, Church SE, Hether TD, Xu J, Gohil M, Buckingham TH, Yee SS, Gonzalez VE, Kulikovskaya I, Chen F, Tian L, Tien K, Gladney W, Nobles CL, Raymond HE; Prostate Cancer Cellular Therapy Program Investigators; Hexner EO, Siegel DL, Bushman FD, June CH, Fraietta JA, Haas NB. PSMA-targeting TGFβ-insensitive Armored CAR T-cells in Metastatic Castration Resistant Prostate Cancer: a Phase 1 Trial , Nat Med, 28(4): 2022,724-734

Jonasch E, Donskov F, Iliopolous O, Rathmell WK, Narayan V, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini R, Linehan WM, Srinivasan R. Belzutifan for Von Hippel-Lindau Disease–Associated Renal Cell Carcinoma , New Engl J Medicine , 385(22): 2021,2036-2046

Dorff TB, Narayan V, Forman SJ, Zang PD, Fraietta JA, June CH, Haas NB, Priceman SJ. Novel Redirected T Cell Immunotherapies for Advanced Prostate Cancer , Clin Cancer Res, 28(4): 2021,576-584

Pal SK, Tangen C, Thompson IM Jr, Balzer-Haas N, George DJ, Heng DYC, Shuch B, Stein M, Tretiakova M, Humphrey P, Adeniran A, Narayan V, Bjarnason GA, Vaishampayan U, Alva A, Zhang T, Cole S, Plets M, Wright J, Lara PN Jr. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial , Lancet, 397(10275): 2021,695-703

Sharma P, Pachynski RK, Narayan V, Fléchon A, Gravis G, Galsky MD, Mahammedi H, Patnaik A, Subudhi SK, Ciprotti M, Simsek B, Saci A, Hu Y, Han GC, Fizazi K. Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial , Cancer Cell, 38(4): 2020,489-499

Narayan, V.; Harrison, M.; Cheng, H.; Kenfield, S.; Aggarwal, R.; Kwon, D.; McKay, R.; Hauger, R.; Hart, N.; Conzen, S.; Borno, H.; Jim, H.; Dicker, A.; Dorff, T.; Moslehi, J.; Mucci, L.; Parsons, JK.; Saad, F.; Soule, H.; Morgans, A.; Ryan, CJ. Improving Research for Prostate Cancer Survivorship: A Statement from the SuRECaP (Survivorship Research in Prostate Cancer) Working Group , Urologic Oncology: Seminars and Original Investigations, 38(3): 2020,83-93

Narayan, V.; Puligandla, M.; Haas, NB.; Subramanian, P.; DiPaola, RS.; Uzzo, R. Patterns of Relapse and Implications for Post-Nephrectomy Surveillance for Patients with High-Risk Non-Clear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 3 ECOG-ACRIN E2805 Trial , J Urol, 201(1): 2019,62-68

Narayan, V.; Keefe, S.; Haas, NB.; Wang, L.; Puzanov, I.; Putt, M.; Catino, A.; Fang, J.; Agarwal, N.; Hyman, D.; Smith, AM.; Finkelman, B.; Narayan, HK.; Ewer, S.; ElAmm, C.; Lenihan, D.; Ky, B. Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma , Clin Cancer Res, 23(14): 2017,3601-3609

Yu E, Narayan V, Esposito G, Szmulewitz R, Lu Y, Lilly MB, Calais J, Bratslavsky G, Menda Y, Vasanawala M, Pouliot F, Laidley D, Fleshner N, Saad F, Provost JC, Teslenko I, Rawat NK, Ulaner G. 131I-LNTH-1095 Radioligand Therapy Plus Enzalutamide vs. Enzalutamide Alone in Men With PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Study , Clin Canc Res, 15(32(10)): 2026,1973-1982

Jung IY, Bartoszek RL, Rech AJ, Collins SM, Ooi SK, Williams EF, Hopkins CR, Narayan V, Haas NB, Frey NV, Hexner EO, Siegel DL, Plesa G, Porter DL, Cantu A, Everett JK, Guedan S, Berger SL, Bushman FD, Herbst F, Fraietta JA. Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T cell-intrinsic Dysfunction , Cancer Discov, 13(7): 2023,1636-1655